Comparative Pharmacology
Head-to-head clinical analysis: MD 76R versus OXILAN 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 76R versus OXILAN 300.
MD-76R vs OXILAN-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
Iodinated contrast agent that attenuates X-rays and enhances vascular and tissue visualization during imaging procedures.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
Intravenous: 1-2 mL/kg (300 mg iodine/mL) for contrast imaging; maximum dose 2 mL/kg per procedure.
None Documented
None Documented
Terminal half-life 1-2 hours; prolonged in renal impairment.
Terminal half-life: 1.5–2.5 hours (normal renal function); prolonged in renal impairment (up to 30 hours in severe impairment).
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Renal elimination: 100% unchanged via glomerular filtration; biliary/fecal excretion negligible (<1%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent